News and features

Scientists at the ICR have found an important new drug target for advanced bowel cancer

Strength of early results means all 'placebo arm' trial patients will be offered treatment with RG7204.

These findings, from the largest randomised trial of IMRT in head and neck cancer

Cancer Research UK-funded scientists have discovered that skin cancer can spread to the lungs when a gene in an important cell communication pathway is blocked.

Prostate cancer patients under Active Surveillance could be assessed by MRI instead of an invasive biopsy

A breakthrough study has shed light on the reason why advanced cancers are notoriously resistant to treatment and, remarkably, it may be as fundamental as evolution itself.

Since the completion of the Human Genome Project in 2001 there has been an explosion in the amount of genetic information available to researchers involved in drug discovery. As faster technologies continue to fuel the growth of large datasets, researchers at the ICR and elsewhere must develop new methods for distilling useful information from an overwhelming amount of data.

Biotechnology company BioVex Inc has announced the start of a Phase III study using the drug OncoVEX, a genetically engineered cold sore virus, to treat patients newly-diagnosed with locally advanced head and neck cancer

Adding a second drug to standard chemotherapy treatment can help patients diagnosed with an aggressive type of bone marrow cancer live longer.

Men who have long index fingers are at lower risk of prostate cancer, a new study from the ICR has found.

Dr Janine Erler from the ICR has been named as one of the UK’s most impressive professional women.

A powerful new cancer drug discovery database has been launched to speed up the process of bringing drugs from ‘bench to bedside’.